Compare Abercrombie & Fitch Co. (ANF) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abercrombie & Fitch Co. vs BioNano Genomics Inc — how do they compare? Abercrombie & Fitch Co. trades at $113.06 (market cap $5.24B), while BioNano Genomics Inc trades at $1.2 (market cap $13.66M). The key difference: Abercrombie & Fitch Co. is far larger — about 383.6× BioNano Genomics Inc's market cap, and Abercrombie & Fitch Co. is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| ANF | BNGO | |
|---|---|---|
Market Cap | $5.24B | $13.66M |
Sector | Consumer Cyclical | Health |
52-Week High | $129.85 | $4.92 |
52-Week Low | $65.61 | $1.06 |
Enterprise Value | $5.91B | $16.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ANF trades at $113.06, down 4.61% on the day, but maintains strong fundamentals with a P/E of 11.41 and robust profitability margins. The stock exhibits a bullish technical trend with moving averages supporting upside, though oscillators signal overbought conditions. Recent earnings beats and a return to positive cash flow in 2026 highlight operational strength, while institutional interest grows, as seen with Amundi's increased stake in Q2 2026.
Outlook remains positive driven by earnings momentum and valuation appeal, but risks include Hollister brand headwinds and geopolitical tensions affecting EMEA growth. Analyst consensus leans bullish with a $112.86 price target, suggesting limited upside from current levels amid near-term volatility.
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
